DLL3-eiwit (C-His, mens)

DLL3

SCDO1

C-His

< 1.0 EU per μg protein as determined by the LAL method.

≥ 95 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC.

1.Immobilized Recombinant Human DLL3 Protein (ECD, His Tag) (Cat: 20010-H08H5) at 80 ng/mL (100 μL/well) can bind Anti-DLL3 (Research Grade Rovalpituzumab Biosimilar), the EC50 is 3-12 ng/mL (QC tested) . 2.Immobilized Recombinant Human DLL3 Protein (ECD, His Tag) from competitor A and SINO at 80 ng/mL (100 μL/well) can bind Anti-DLL3 (Research Grade Rovalpituzumab Biosimilar), the EC50 is 10 ng/mL and 7.8 ng/mL, respectively. The results demonstrated that SINO DLL3 (Cat. No. 20010-H08H5) has a much higher binding capacity than that of competitor A (Routinely tested) . 3.Anti-DLL3 (Research Grade Rovalpituzumab Biosimilar) captured on Protein A chip, can bind Recombinant Human DLL3 Protein, His Tag (Cat. No. 20010-H08H5) with an affinity constant of 1.056 nM as determined in an SPR assay (Biacore T200) (Routinely tested) . 4.Anti-DLL3 antibody (specific Binding EGFs of DLL3), Human IgG1 captured on Protein A chip, can bind Recombinant Human DLL3 Protein, His Tag (Cat. No. 20010-H08H5) with an affinity constant of 1.457 nM as determined in an SPR assay (Biacore T200) (Routinely tested) . 5.TARLATAMAB-DLLE derived Bispecific T-cell Engager captured on Protein A chip, can bind Recombinant Human DLL3 Protein (ECD, His Tag) (Cat: 20010-H08H5) with an affinity constant of 0.270 nM as determined in an SPR assay (Biacore 8K) (Routinely tested) .

Ala27-Leu492

The recombinant Human DLL3 comprises 488 amino acids and has a predicted molecular mass of 50.68 kDa. It migrates as approximately 57.7 kDa band in SDS-PAGE under reducing conditions.

Human